Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis

Indian Journal of Cancer

Volumn 50, Issue 2, 2013, Pages 135-141

  Pai, P S ^a   Vaidya, A D ^a   Prabhash, K ^a   Banavali, Shripad D ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Chemotherapy; metronomic; oral cancers

Indexed keywords

CELECOXIB; METHOTREXATE; CISPLATIN;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEEK MUCOSA; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG ALVEOLUS; MAINTENANCE THERAPY; MALE; METRONOMIC DRUG ADMINISTRATION; MOUTH SQUAMOUS CELL CARCINOMA; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TERTIARY HEALTH CARE; TONGUE CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HEALTH CARE QUALITY; MOUTH NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADMINISTRATION, METRONOMIC; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MOUTH NEOPLASMS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; STANDARD OF CARE;

EID: 84884331884     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.117024     Document Type: Conference Paper

References (44)

1. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: A global perspective on epidemiology and prognosis. Anticancer Res 1998;18: 4779-86.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94: 153-6.
3. Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: Changing the paradigm that more is better. Curr Oncol 2009;16: 7-15.
4. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4: 423-36.
5. Raina V, Tyagi BB, Manoharan N. Consolidated Report of the Population based Cancer Registries 2001-2004. National Cancer Registry Programme, Indian Council of Medical Research Bangalore; 2006.
6. Yeole BB. Trends in incidence of head and neck cancers in India. Asian Pac J Cancer Prev 2007;8: 607-12.
7. Molina MA, Cheung MC, Perez EA, Byrne MM, Franceschi D, Moffat FL, et al. African American and poor patients have a dramatically worse prognosis for head and neck cancer: An examination of 20,915 patients. Cancer 2008;113: 2797-806.
8. Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005;92: 1341-8.
9. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359: 1143-54.
10. Argiris A, Karamouzis MV. Empowering induction therapy for locally advanced head and neck cancer. Ann Oncol 2011;22: 773-81.
11. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355: 949-55.
12. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92: 4-14.
13. Specenier PM, Vermorken JB. Current concepts for the management of head and neck cancer: Chemotherapy. Oral oncology 2009;45: 409-15.
14. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357: 1695-704.
15. Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol 2007;84: 5-10.
16. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105: 1045-7.
17. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60: 1878-86.
18. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
19. Andre N, Padovani L, Pasquier E. Metronomic scheduling of anticancer treatment: The next generation of multitarget therapy? Future Oncol 2011;7: 385-94.
20. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 2010;7: 455-65.
21. Rentschler RE, Wilbur DW, Petti GH, Chonkich GD, Hilliard DA, Camacho ES, et al. Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas: A prospective, randomized study. J Clin Oncol 1987;5: 278-85.
22. Rao RS, Parikh DM, Parikh HK, Bhansali MB, Deshmane VH, Fakih AR. Perioperative chemotherapy in patients with oral cancer. Am J Surg 1994;168: 262-7.
23. Schifeling DJ, George T, McGuirt F, Capizzi RL, Kamen BA. Methotrexate content in squamous cell carcinoma of the head and neck after low-dose methotrexate. Med Pediatr Oncol 1994;22: 88-90.
24. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60: 1306-11.
25. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37: 179-92.
26. Khan OA, Blann AD, Payne MJ, Middleton MR, Protheroe AS, Talbot DC, et al. Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer 2011;104: 1822-7.
27. Ko SH, Choi GJ, Lee JH, Han YA, Lim SJ, Kim SH. Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma. Oncology reports 2008;19: 425-33.
28. Bock JM, Menon SG, Sinclair LL, Bedford NS, Goswami PC, Domann FE, et al. Celecoxib toxicity is cell cycle phase specific. Cancer Res 2007;67: 3801-8.
29. Kwak YE, Jeon NK, Kim J, Lee EJ. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Ann N Y Acad Sci 2007;1095: 99-112.
30. Lai V, George J, Richey L, Kim HJ, Cannon T, Shores C, et al. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 2008;30: 67-74.
31. Lang S, Picu A, Hofmann T, Andratschke M, Mack B, Moosmann A, et al. COX-inhibitors relieve the immunosuppressive effect of tumor cells and improve functions of immune effectors. Int J Immunopathol Pharmacol 2006;19: 409-19.
32. Raju U, Ariga H, Dittmann K, Nakata E, Ang KK, Milas L. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys 2005;63: 520-8.
33. Terakado N, Shintani S, Yano J, Chunnan L, Mihara M, Nakashiro K, et al. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral oncol 2004;40: 383-9.
34. Raab RE, Walker PR, Bellin LS, Wong JH. The East Carolina Breast Center phase II trial of neoadjuvant metronomic chemotherapy in triple-negative breast cancer. J Clin Oncol 2011;29:(suppl; abstr e11505).
35. Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma. Available from: http://clinicaltrials. gov/ct2/show/study/ NCT00855881?show-desc=Y#desc. [Last accessed on 2013 Jun 27].
36. Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka K, Noguchi K, et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol 2003;23: 665-72.
37. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 1992;10: 1245-51.
38. Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, Shemer S, et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 2010;184: 2449-57.
39. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res 2003;63: 1727-30.
40. van Oijen MG, Slootweg PJ. Oral field cancerization: Carcinogen-induced independent events or micrometastatic deposits? Cancer Epidemiol Biomarkers Prev 2000;9: 249-56.
41. Feng L, Wang Z. Chemopreventive effect of celecoxib in oral precancers and cancers. Laryngoscope 2006;116: 1842-5.
42. Kerr DJ, Midgley R. Can we treat cancer for a dollar a day? Guidelines for low-income countries. N Engl J Med 2010;363: 801-3.
43. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011;364: 2060-5.
44. André N, Banavali S, Snihur Y, Pasquier E. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol 2013;14:e239-48.